BOLD

NASDAQ 已收盘

Boundless Bio

2.32 USD
▼-0.06-2.52%
盘后 2.30 -0.86%
2026-11-20
市值
$54.78M
市盈率
—
EPS
-2.46
股息率
—
52 周区间
0.96 – 3.16
成交量
147.87K
Beta
0.46
目标价
—
52W 低 0.9652W 高 3.16
价格走势

公司简介

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel ...